Wood/biomass smoke particulate materials (WBSPM) are pneumotoxic, but the mechanisms by which these materials affect lung cells are not fully understood. We previously identified transient receptor potential (TRP) ankyrin-1 as a sensor for electrophiles in WBSPM and hypothesized that other TRP channels expressed by lung cells might also be activated by WBSPM, contributing to pneumotoxicity. Screening TRP channel activation by WBSPM using calcium flux assays revealed TRPV3 activation by materials obtained from burning multiple types of wood under fixed conditions. TRPV3 activation by WBSPM was dependent on the chemical composition, and the pattern of activation and chemical components of PM agonists was different from that of TRPA1. Chemical analysis of particle constituents by gas chromatography-mass spectrometry and principal component analysis indicated enrichment of cresol, ethylphenol, and xylenol analogues, plus several other chemicals among the most potent samples. 2,3-, 2,4-, 2,5-, 2,6-, 3,4-, and 3,5-xylenol, 2-, 3-, and 4-ethylphenol, 2-methoxy-4-methylphenol, and 5,8-dihydronaphthol were TRPV3 agonists exhibiting preferential activation versus TRPA1, M8, V1, and V4. The concentration of 2,3- and 3,4-xylenol in the most potent samples of pine and mesquite smoke PM (<3 μm) was 0.1-0.3% by weight, while that of 5,8-dihydronaphthol was 0.03%. TRPV3 was expressed by several human lung epithelial cell lines, and both pine PM and pure chemical TRPV3 agonists found in WBSPM were more toxic to TRPV3-over-expressing cells via TRPV3 activation. Finally, mice treated sub-acutely with pine particles exhibited an increase in sensitivity to inhaled methacholine involving TRPV3. In summary, TRPV3 is activated by specific chemicals in WBSPM, potentially contributing to the pneumotoxic properties of certain WBSPM.
Wood/biomass smoke particulate materials (WBSPM) are pneumotoxic, but the mechanisms by which these materials affect lung cells are not fully understood. We previously identified transient receptor potential (TRP) ankyrin-1 as a sensor for electrophiles in WBSPM and hypothesized that other TRP channels expressed by lung cells might also be activated by WBSPM, contributing to pneumotoxicity. Screening TRP channel activation by WBSPM using calcium flux assays revealed TRPV3 activation by materials obtained from burning multiple types of wood under fixed conditions. TRPV3 activation by WBSPM was dependent on the chemical composition, and the pattern of activation and chemical components of PM agonists was different from that of TRPA1. Chemical analysis of particle constituents by gas chromatography-mass spectrometry and principal component analysis indicated enrichment of cresol, ethylphenol, and xylenol analogues, plus several other chemicals among the most potent samples. 2,3-, 2,4-, 2,5-, 2,6-, 3,4-, and 3,5-xylenol, 2-, 3-, and 4-ethylphenol, 2-methoxy-4-methylphenol, and 5,8-dihydronaphthol were TRPV3 agonists exhibiting preferential activation versus TRPA1, M8, V1, and V4. The concentration of 2,3- and 3,4-xylenol in the most potent samples of pine and mesquite smoke PM (<3 μm) was 0.1-0.3% by weight, while that of 5,8-dihydronaphthol was 0.03%. TRPV3 was expressed by several human lung epithelial cell lines, and both pine PM and pure chemical TRPV3 agonists found in WBSPM were more toxic to TRPV3-over-expressing cells via TRPV3 activation. Finally, mice treated sub-acutely with pine particles exhibited an increase in sensitivity to inhaled methacholine involving TRPV3. In summary, TRPV3 is activated by specific chemicals in WBSPM, potentially contributing to the pneumotoxic properties of certain WBSPM.
Wood and biomass smoke emissions are frequent
indoor and outdoor
air pollutants and a major public health concern.[1,2] Wood/biomass
smoke particulate materials (WBSPM) form by condensation of semi-volatile
chemicals in smoke plumes and are chemically distinct from many other
forms of environmental PM. However, mechanisms by which WBSPM affect
the lungs and human health are not fully understood.Wood and
biomass particles are pneumotoxic. Episodic exposures
for humans (typically in the range of 0.1–1 mg/m3 for a few hours to days) can result from nearby forest and range
fires, crop burning, and the occasional use of wood stoves and fireplaces
in homes. Chronic exposures occur frequently in under-developed locations
where biomass is burned for heat and in open, poorly ventilated, inefficient
cook stoves. Billions of people are exposed to WBSPM as a result of
their reliance on wood/biomass as a primary fuel source, with exposures
often reaching levels as high as 8–9 mg/m3 for multiple
hours per day, for multiple years.[1,2]Pulmonary
irritation, altered pulmonary immune functions, exacerbation
of asthma and cardiovascular diseases, increased rates of respiratory
infections, and increased risks for developing chronic obstructive
pulmonary disease (COPD)/emphysema have been linked to WBSPM
exposure.[3−8] For example, WBSPM (PM10 typically exceeding 0.15–0.2
mg/m3) has been correlated with increased rates of hospital
visits for respiratory complications, including the exacerbation of
asthma and COPD.[9−18] A formative study in which wood stoves in homes in Libby, MT, USA,
were replaced with low-emission wood stoves reported ∼30% lower
ambient PM2.5 attributed to reduced WBSPM emissions, which
correlated with a 20–60% reduction in respiratory infections
and other health-related end points among children.[19] Finally, meta-analysis studies estimate a ∼2-fold
greater risk for developing COPD associated with WBSPM exposure[20−23] and odds ratios of 1.5–2.3 associated with living in households
using biomass fuels for cooking, versus cleaner fuels.[24,25]Oxidants, reactive oxygen species, and other reactive chemicals
are known to contribute to the acute pro-inflammatory and cytotoxic
effects of WBSPM.[26−29] We previously characterized the activation of the electrophile/oxidant-sensitive
transient receptor
potential ankyrin-1 (TRPA1) ion channel in cultured mouse trigeminal
neurons and A549 cells by electrophiles and resin acids found in pine
and mesquite PM.[30] TRPA1 activation in
C-fiber neurons is a mechanism by which WBSPM likely irritates the
airways and promotes cough and neurogenic inflammation/edema.Unlike in A549 cells, TRPA1 is typically expressed at low/non-detectable
levels in normal human lung epithelial cells. However, these cells
are also impacted in specific ways by WBSPM. In A549 cells, we reported
that the TRPA1 antagonist HC-030031 failed to fully inhibit Ca2+ flux caused by pine PM.[30] In
preliminary studies we also found that primary human lung epithelial
cells lacking TRPA1 mRNA expression and Ca2+ flux in response
to prototypical TRPA1 agonists exhibited Ca2+ flux following
wood smoke PM treatment that was not affected by a TRPA1 antagonist.
Combined, these data suggested the existence of additional wood smoke-sensitive
Ca2+ channels in lung epithelial cells, which may be relevant
to the toxic effects of WBSPM on these cells. Here, we report activation
of TRPV3 by specific chemicals present in selected wood smoke PM,
TRPV3 expression by multiple human lung epithelial lines, and a role
for TRPV3 in WBSPM cytotoxicity in vitro and airway
hypersensitivity inmice.
Experimental Procedures
Chemicals
Chemicals were purchased from Sigma-Aldrich
(St. Louis, MO) or Thermo-Fisher Scientific (Waltham, MA) unless otherwise
specified. The TRPV3 antagonist 2-(5-trifluoromethyl-pyridine-2-ylsulfanyl)-1-(8-methyl-3,4-dihydro-2H-quinolin-1-yl)-ethanone (TRPV3 antagonist) was synthesized
as previously described.[31]
Wood Smoke
Particles
Size-fractionated wood smoke PM
was produced as previously described.[30] Approximately 10 g portions of fresh, wet, aged, or dry Austrian
pine, mesquite chips, and scrub oak collected from the foothills of
Salt Lake Valley were burned in a laboratory furnace, and the PM was
collected using an Anderson cascade impactor. Depending upon the fuel
source, the yield of PM was 0.2–2%.
Diesel Exhaust Particles
(DEPs)
DEPs were from three
sources: the tailpipe of an on-road “black smoker” 2004
Ford F350 truck (Black Smoker), heavy truck diesel particle filter
regeneration/cleaning (Filter DEP), and NIST (SRM2975). DEPs were
either suspended in treatment solutions as described below or extracted
with ethanol to produce an oily, tar-like material previously shown
to be enriched in TRPA1 agonists, and similar in consistency to the
wood smoke PM used in this study.[30,32]
Preparation
of Wood Smoke Particle/Diesel Exhaust Particle Extract
Treatment Solutions
Each material/residue was re-suspended
in DMSO to an initial concentration of 230 mg/mL and subsequently
diluted to the final working concentrations in cell culture media.
For cell treatments, the final concentration of DMSO in the treatment
solutions was ≤1% (v/v). For screening TRP channel activation,
concentrations of 0, 0.58, 1.15, and 2.3 mg/mL extract (equivalent
to 0, 45, 90, and 180 μg/cm2) were used.
Cells
Cells were maintained in a humidified cell culture
incubator at 37 °C with a 95% air:5% CO2 atmosphere.
HEK-293 cells (ATCC; Rockville, MD) were cultured in DMEM:F12
media containing 5% fetal bovine serum and 1x penicillin/streptomycin.
HumanTRP channel over-expressing HEK-293 cells were generated as
previously described[33,34] and were cultured in DMEM:F12
media containing 5% fetal bovine serum, 1x penicillin/streptomycin,
and Geneticin (300 μg/mL). Humanadenocarcinoma (A549)
cells (ATCC; Rockville, MD) were cultured in DMEM containing 5% FBS
and 1x penicillin/streptomycin. BEAS-2B cells were grown in LHC-9
media. HumanTRPV3 over-expressing BEAS-2B cells (TRPV3-OE) were created
by transfecting BEAS-2B cells with a pcDNA3.1-TRPV3-V5/His expression
plasmid. TRPV3-OE cells were selected using Geneticin (300 μg/mL);
individual colonies were isolated, expanded, and subsequently screened
for increased TRPV3 agonist-induced calcium flux and TRPV3 mRNA and
protein expression. Data illustrating TRPV3 over-expression in the
TRPV3-OE cells used in this study are collected in Supplementary Figure 1. Normal human bronchial epithelial
cells (NHBE; donor IDs 14664, 31442, and 9999-1) were purchased from
Lonza (Walkersville, MD). Human lobar bronchial epithelial cells (Lobar;
donor ID 01344) were purchased from Lifeline Cell Technology (Frederick,
MD). All primary cells were maintained for no more than five passages
according to supplier recommendations.
Calcium Imaging Assays
Calcium flux/TRPV3 activity
was assayed using the Fluo-4 Direct assay kit (Invitrogen). Treatment-induced
changes in cellular fluorescence were quantified from fluorescence
micrographs or using a NOVOStar fluorescence plate reader (BMG Labtech;
Offenberg, Germany), as previously described.[30−34] All agonist treatment solutions were prepared in
LHC-9 at 3× concentration and added to cells at 37 °C. Particles
were added based on the surface area of the vessel (μg/cm2). Data from HEK-293TRP-over-expressing cells were corrected
for non-specific responses, if any, observed with HEK-293 cells. Data
were also either normalized to the maximum attainable change in fluorescence
elicited by ionomycin (10 μM) post-treatment or to the change
elicited by a maximum stimulatory concentration of a positive control
agonist, as noted in the figure legends.
Identification of Novel
TRPV3 Agonists in PM
Analysis
of chemical components comprising the various PM samples was performed
at the University of Utah Metabolomics Core facility. Assays were
performed on a Waters GCT Premier mass spectrometer fitted with an
Agilent 6890 gas chromatograph and a Gerstel MPS2 auto sampler. Samples
in DMSO (approximately 10 mg/mL) were diluted to 1 mg/mL in pyridine
and then transferred to auto sampler vials, and 1 μL of the
sample was injected into the inlet held at 250 °C using split
mode at a 10:1 split ratio. The gas chromatograph had an initial temperature
of 95 °C for 1 min followed by a 40 °C/min ramp to 110 °C
and a hold time of 2 min. This was followed by a second 5 °C/min
ramp to 250 °C, a third ramp to 350 °C, then a final hold
time of 3 min. A 30 m Restek Rxi-5 MS column with a 5 m guard column
was employed for chromatographic separation. Data were collected using
MassLynx 4.1 software (Waters) and a text file containing the area
under the curve for all of the analyte peaks was generated. Principle
component analysis (PCA) and partial least-squares discriminate analysis
(PLS-DA) was performed either using SIMCA-P 12.0 (Umetrics,
Kinnelon, NJ) or Metaboanalyst 3.0 (http://www.metaboanalyst.ca/). Analytes showing high correlation with TRPV3 potency were preliminarily
identified via spectral matching using the GC-EIMS (NIST 08) spectral
database, and subsequent comparisons to purchased standards. The potency
and selectivity of the potential TRPV3 agonists was determined by
quantifying TRP channel activation (Ca2+ flux) in HEK-293
and/or BEAS-2BTRP channel over-expressing cells, as described above.
Additional confirmations of agonists and quantification of selected
analytes in WBSPM was performed using an Agilent GC-MSD equipped with
a 30 m DB-5 MS (0.25 μm i.d.; 0.25 μm film thickness)
column. For quantification the following assay parameters were used:
extracts were diluted to 1 mg/mL in methylene chloride, transferred
to auto sampler vials, and 4 μL of the sample was injected into
the inlet held at 300 °C using splitless mode. The gas chromatograph
had an initial temperature of 55 °C for 0.5 min followed by a
10 °C/min ramp to 225 °C, followed by a 50 °C/min ramp
to 325 °C, and a hold time of 5 min. Samples were assayed in
either scan mode to identify new analytes or SIM mode using m/z values of 108 (cresols), 122 (xylenols),
146 (5,8-dihydro-1-naphthol), and 206 (2,4-di-tert-butylphenol/internal standard).
Acute Cytotoxicity Assay
Cytotoxicity assays were performed
in 96-well plates with 24 h incubations and assessment of residual
cell viability using the Dojindo Cell Counting Kit 8 (Dojindo; Rockville,
MD). Cells were plated 24–48 h prior to treatment and were
treated at 85–90% confluence.
qPCR Gene Expression
A549, BEAS-2B, and Lobar cells
were cultured in 25 cm2 flasks. Three passages for each
cell type were collected for biological replicates. NHBE cells from
three donor samples were cultured in 12-well plates. At 80% confluence,
cells were harvested and total RNA was isolated using the GenElute
Mammalian Total RNA Miniprep Kit (Sigma; St. Louis, MO). Total RNA
(1 μg) was converted to cDNA using iScript Reverse Transcription
Supermix (BioRad; Hercules, CA). The cDNA was diluted 1:1 for analysis
by quantitative real-time PCR (qPCR) using a Life Technologies QuantStudio
6 Flex instrument and the TaqMan probe-based assays for humanTRPV3
(Hs00376854_m1) and humanTRPA1 (Hs00175798_m1). Values for TRPA1
and TRPV3 were normalized to β2-macroglobulin (β2M; Hs00984230_m1)
and quantification TRP channel mRNA expression was calculated using
a standard curve.
TRPV3 Western Blot
Protein was isolated
from cells
using RIPA lysis buffer (Thermo Scientific; Rockford, IL) supplemented
with Halt protease inhibitor cocktail (Thermo Scientific; Rockford,
IL). The cell lysate was sonicated at 50% amplitude for 2 s, three
times, and centrifuged at 12000g for 5 min. Protein
concentration was measured using the BCA assay (Pierce; Rockford,
IL). Total protein lysate obtained from TRPV3-OE BEAS-2B cells was
used as a positive control (0.25 μg/lane). Protein (25 μg)
was loaded into a 4–12% Bis-Tris gel (Thermo Scientific; Rockford,
IL). TRPV3 protein expression was assessed using a TRPV3mouse primary
antibody (75-043; NeuroMab; Davis, CA (1:1000)) and a donkey anti-mouse
HRP secondary antibody (NA931VS; GE Healthcare Lifesciences (1:10000)).
Protein expression/band density was quantified using Image-J and normalized
to total protein from amido black post-stained membranes as previously
described.[35] The TRPV3 band was observed
at ∼90 kDa.
RNA Sequencing
RNA sequencing was
performed by the
High Throughput Genomics Core Facility at the Huntsman Cancer Institute,
University of Utah. BEAS-2B and TRPV3-OE BEAS-2B cells were harvested
using trypsin and total RNA was isolated using the RNeasy mini kit
with on column DNase I digestion (Qiagen). RNA quality was assessed
by RNA nanochip technology and library construction was performed
using the Illumina TruSeq Stranded mRNA Sample Preparation kit using
established protocols. The sequencing libraries (18 pM) were then
chemically denatured and applied to an Illumina TruSeq v3 single-read
flow cell using an Illumina cBot. Hybridized molecules were clonally
amplified and annealed to sequencing primers with reagents from an
Illumina TruSeq SR Cluster Kit v3-cBot-HS (GD-401-3001). Following
transfer of the flow cell to an Illumina HiSeq instrument (HCS v2.0.12
and RTA v1.17.21.3), a 50-cycle single-read sequence run was performed
using TruSeq SBS v3 sequencing reagents (FC-401-3002). Raw data were
processed by the University of Utah Bioinformatics core to quantify
differential mRNA expression between the two cell types. The data
presented in this publication have been deposited in NCBI’s
Gene Expression Omnibus[36] and are accessible
through GEO Series accession number (GSE109598).
Mice
Experimental protocols were approved by the University
of Utah Animal Care and Use Committee. Male C57BL/6 mice (Jackson
Laboratories (20–25 g; 6–8 weeks old)) were used. Mice
were housed in an AAALAC-approved vivarium maintained with 12 h/12
h light/dark cycles, at 23–26 °C and 40–50% relative
humidity. Standard lab chow and water were provided ad libitum. Fresh pine PM (resuspended daily in DMSO) was dosed at 0.5 mg/kg
(12.5 μg total PM/dose) every other day via the oropharyngeal
route, with analysis and necropsy 24 h after the third dose. The dosing
scheme is illustrated in Figure A and is similar to that reported by Nemmar
et al. using diesel exhaust PM.[37] The 0.5
mg/kg dose (12.5 μg of PM1.1–2) corresponds
to the amount PM collected from burning 6–7 mg of pine. This
dose represents an approximate area dose of 10–20 ng/cm2, estimated using an surface area of 600 cm2 for
an adult mouse lung,[38] and assuming 50–100%
delivery and retention of the oropharyngeal dose in the lungs. This
dose roughly approximates the 2–25 ng/cm2 area dose
that is predicted if a human were exposed to WBSPM at 5000 μg/m3 for 8–24 h/day assuming a lung surface area of 70
m2 and exchange of ∼458 L of air/h with 10–30%
deposition throughout the respiratory tract for adult humans. This
level of exposure for humans is on the high side, but plausible, and
represents a scenario for which acute adverse responses and effects
on human health have been reported.[1,2] Mice receiving
the TRPV3 antagonist were injected i.p. (150 μL) with 1 mg/kg
antagonist diluted from a DMSO stock in saline (DMSO = 1%) 1 h before
pine exposure. Additionally, mice were co-treated with 1 μM
TRPV3 antagonist diluted in the pine PM suspensions (DMSO = 1%) via
the oropharyngeal route.
Figure 11
(A)
Methacholine dose–response curves for changes in airway
resistance in saline (black; n = 5), pine PM-treated
(gray; n = 5), TRPV3-antagonist treated (dashed black; n = 5), and pine + TRPV3-antagonist cotreated (dashed gray; n = 5) C57BL/6 mice. Data are the mean ± standard error
of the mean (n = 5). Data were analyzed by two-way
ANOVA and a Bonferroni post-test comparing all groups: Differences
compared to saline treatment are indicated as p <
0.05 (*), p < 0.01(**). (B) Comparison of changes
in airway resistance at the 25 mg/mL methacholine dose. Data are the
mean ± standard error of the mean (n = 5) and
were analyzed by one-way ANOVA with a Newman–Keuls post-test; p < 0.05 (*), p < 0.01(**).
Pulmonary Mechanics
Airway resistance,
compliance,
and elastance were measured in anesthetized (ketamine + xylazine 100
+ 20 mg/kg), paralyzed (0.1 mg/kg vecuronium bromide), and tracheostomized
mice using a computer controlled small animal ventilator (Flexivent
FX1; SCIREQ Inc., Montreal, Qc, Canada) as previously described.[39] Baseline measurements were collected for each
mouse followed by assessment of bronchial reactivity/contractility
elicited by serial delivery of increasing concentrations of aerosolized
methacholine using the Flexivent Aeroneb fine particle nebulizer (0,
3.125, 6.25, 12.5, 25, and 50 mg/mL) in saline for 10 s per dose at
4–5 min intervals. The area under the curve value for measured
criteria was calculated at each methacholine dose using a single-compartment
model to generate methacholine dose–response curves. Each treatment
group consisted of five age-matched mice.
Statistical Analysis
Values generally represent the
mean ± SEM. One-way or two-way ANOVA with post-testing at the
95% confidence interval was used to determine significance, as indicated
in each figure legend.
Results
TRP Channel Activation
by Pine and Mesquite Wood Smoke PM
HumanTRP channel activation
by pine and mesquite PM was evaluated.
HEK-293 cells over-expressing TRPA1, C4, M2, M8, V1, V2, V3, or V4
were treated with pine and mesquite PM (0.65–1.1 μm)
at 0.73 mg/mL (equivalent to 57 μg/cm2), and positive
controls for each TRP channel. Ca2+ flux was observed in
TRPA1 and TRPV3-over-expressing cells (Figure A). The calcium response in these cells was
comparable in both rate and magnitude to the respective positive controls
(TRPA1 = AITC at 150 μM and TRPV3 = carvacrol at 300 μM).
Activation of TRPA1 by pine and mesquite PM was previously reported
by our group,[30] but TRPV3 activation was
novel. Analysis of TRPV3 activation by pine and mesquite PM of different
size ranges (0.43 → 10 μm; stages 0–7 of on the
Anderson cascade impactor) demonstrated that PM < 2.1 μm
(stages 5–7 on the Anderson cascade impactor) were most potent
(Figure B). Furthermore,
pine PM was more potent on a mass basis than mesquite PM (Figure B,C).
Figure 1
(A) TRP channel activation/calcium
flux data for TRP-specific/positive
control agonists (white), pine PM (gray; 0.73 mg/mL, 57 μg/cm2), and mesquite PM (black; 0.73 mg/mL, 57 μg/cm2) in TRP channel over-expressing HEK-293 cells. Data are normalized
to ionomycin (10 μM). Positive controls for each channel include
TRPA1-AITC (150 μM), TRPC4-carbachol (750 nM), TRPM2-H2O2 (1 mM), TRPM8-icilin (20 μM), TRPV1-capcascin
(20 μM), TRPV2-THC (100 μM), TRPV3-carvacrol (300 μM),
TRPV4-GSK (25 nM). *, statistically significant responses (p < 0.05) relative to vehicle controls, determined by
the analysis of each cell type individually using one-way ANOVA and
a Dunnett post-test (α = 0.05). (B) Calcium flux data for different
size fractions (Anderson Cascade impactor stages 0–7 (S0–7))
of pine and mesquite smoke PM (0.73 mg/mL; 57 μg/cm2), normalized to the positive control for TRPV3 (carvacrol; 300 μM).
*, Statically significant responses (p < 0.05)
relative to vehicle controls; #, statistically significant responses
(p < 0.05) relative to pine as determined using
a two-way ANOVA using and the Bonferonni post-test. (C) EC50 values for TRPV3 activation by pine and mesquite PM (0.65–1.1
μm) in TRPV3-over-expressing HEK-293 cells. Data were collected
using a BMG Labtech NOVOstar plate reader and are represented as the
mean ± standard error of the mean (n ≥
3).
(A) TRP channel activation/calcium
flux data for TRP-specific/positive
control agonists (white), pine PM (gray; 0.73 mg/mL, 57 μg/cm2), and mesquite PM (black; 0.73 mg/mL, 57 μg/cm2) in TRP channel over-expressing HEK-293 cells. Data are normalized
to ionomycin (10 μM). Positive controls for each channel include
TRPA1-AITC (150 μM), TRPC4-carbachol (750 nM), TRPM2-H2O2 (1 mM), TRPM8-icilin (20 μM), TRPV1-capcascin
(20 μM), TRPV2-THC (100 μM), TRPV3-carvacrol (300 μM),
TRPV4-GSK (25 nM). *, statistically significant responses (p < 0.05) relative to vehicle controls, determined by
the analysis of each cell type individually using one-way ANOVA and
a Dunnett post-test (α = 0.05). (B) Calcium flux data for different
size fractions (Anderson Cascade impactor stages 0–7 (S0–7))
of pine and mesquite smoke PM (0.73 mg/mL; 57 μg/cm2), normalized to the positive control for TRPV3 (carvacrol; 300 μM).
*, Statically significant responses (p < 0.05)
relative to vehicle controls; #, statistically significant responses
(p < 0.05) relative to pine as determined using
a two-way ANOVA using and the Bonferonni post-test. (C) EC50 values for TRPV3 activation by pine and mesquite PM (0.65–1.1
μm) in TRPV3-over-expressing HEK-293 cells. Data were collected
using a BMG Labtech NOVOstar plate reader and are represented as the
mean ± standard error of the mean (n ≥
3).
Characteristics of TRPV3
and TRPA1 Activation by Different WBSPM
Samples
PM was collected from burning fresh cut, wet, aged,
and dry pine; mesquite wood chips (two separate burnings denoted by
“a” and “b”), and scrub oak. Ethanol extracts
of three different diesel exhaust particle samples were also prepared.
An equal mass of each material (2.3 mg/mL equivalent to 180 μg/cm2) was applied to TRPV3-over-expressing HEK-293 cells and Ca2+ flux was quantified (Figure A). PM < 2.1 μm (stages 5–7 of the
cascade impactor) from fresh pine and mesquite wood were the most
potent TRPV3 agonists. Specific activation of TRPV3 was not observed
with extracts of the DEP materials, pine and mesquite PM > 5 μm
(stages 0–2 of the cascade impactor), or scrub oak PM. Of significance,
the relative activity of these wood smoke and DEP extract materials
differed from TRPA1 (Figure B), suggesting differences in the relative abundance of TRPA1
and V3 agonists in these materials.
Figure 2
(A) Calcium flux in TRPV3-over-expressing
HEK-293 cells treated
with various PM at 0.73 mg/mL; 57 μg/cm2), normalized
to carvacrol (300 μM). Red is used to indicate the high potency
wood smoke PM samples, green are the DEP extracts, and blue is low
potency wood smoke PM. Different size fractions of the WSPM is represented
by size/impactor stage number (S0–7) as defined in Figure B. These three categories
were used for grouping and PCA + PLS-DA analysis in Figure . (B) Calcium flux in TRPA1-over-expressing
HEK-293 cells treated with various PM at 0.73 mg/mL; 57 μg/cm2), normalized to allyl-isothiocyanate (150 μM). The
color scheme and order of PM is the same as panel A to facilitate
comparisons between TRPV3 and TRPA1 activation by the same materials.
(A) Calcium flux in TRPV3-over-expressing
HEK-293 cells treated
with various PM at 0.73 mg/mL; 57 μg/cm2), normalized
to carvacrol (300 μM). Red is used to indicate the high potency
wood smoke PM samples, green are the DEP extracts, and blue is low
potency wood smoke PM. Different size fractions of the WSPM is represented
by size/impactor stage number (S0–7) as defined in Figure B. These three categories
were used for grouping and PCA + PLS-DA analysis in Figure . (B) Calcium flux in TRPA1-over-expressing
HEK-293 cells treated with various PM at 0.73 mg/mL; 57 μg/cm2), normalized to allyl-isothiocyanate (150 μM). The
color scheme and order of PM is the same as panel A to facilitate
comparisons between TRPV3 and TRPA1 activation by the same materials.
Figure 3
PLS-DA
scores plot showing the relationship between PM potency
and GC/MS chromatographic components shared among the most potent
wood smoke PM (red), least potent wood smoke PM (blue), and DEP (green).
Data analysis and graphics were generated using Metaboanalyst 3.0.
Identification of TRPV3
Agonists in Wood Smoke PM
The
chemical basis for TRPV3 activation by WBSPM was further explored.
Equal quantities of materials from Figure were assayed by high-resolution GC/MS and
the chromatographic and spectral data processed using principal component
analysis (PCA) and partial least-squares discriminant analysis (PLS-DA)
(Figure ). The most
potent TRPV3 activating WBSPM (red), the essentially inactive WBSPM (blue), and DEP samples (green) clustered as independent
groups based on similarities/differences in their chemical compositions
(A heat map illustrating the chemical diversity, similarities, and
differences is shown as Supplementary Figure 2). A list of chemicals associated with the most potent TRPV3 activating
PM was generated by matching the EI mass spectra with entries in the
NIST08 database (Supplementary Table 1).PLS-DA
scores plot showing the relationship between PM potency
and GC/MS chromatographic components shared among the most potent
wood smoke PM (red), least potent wood smoke PM (blue), and DEP (green).
Data analysis and graphics were generated using Metaboanalyst 3.0.Candidate molecules were then
purchased and screened for TRPV3
agonist activity in hTRPV3-over-expressing HEK-293 cells (see Supplementary Table 1 for a summary of the compounds
assayed). In our initial screens, three compounds activated TRPV3: 2,3-xylenol, 3,4-xylenol, and 5,8-dihydronaphthol (Figure ). Of note, 2,5-xylenol was
known to be a TRPV3 agonist.[40] Relative
GC/MS peak areas of 2,3- and 3,4-xylenol (combined), o-, m-, p-cresol (combined), and
5,8-dihydro-1-naphtol across the various WBSPM samples are shown in Figure A; those of the TRPA1
agonists perinaphthenone, 1,2- and 1,4-naphthoquinone (combined),
and the polycyclic aromatic hydrocarbon (PAH) pyrene (used as a general
comparator) are shown in Figure B.
Figure 4
Dose–response relationships for the activation
of human
TRPA1 and TRPV3 channels over-expressed in HEK-293 cells by chemicals
identified in WBSPM. Data are the mean and SEM for n ≥ 3 replicates. (A) 2,3-xylenol, (B) 2,4-xylenol, (C) 2,5-xylenol,
(D) 2,6-xylenol, (E) 3,4-xylenol, (F) 3,5-xylenol, (G) 2-ethylphenol,
(H) 3-ethylphenol, (I) 4-ethylphenol, (J) 2-methoxy-4-methylphenol,
(K) 5,8-dihydro-1-naphthol, and (L) 2,4-di-tert-butylphenol.
Figure 5
(A) Relative peak areas for GC/MS peaks preliminarily
identified
as 2,3- and/or 3,4-xylenol (white bars), 5,8-dihydro-1-naphthol (gray
bars), and o-, m-, and/or p-cresol (black bars) for each of the samples tested as
TRPV3 agonists and assayed by PCA + PLS-DA. (B) Relative peak areas
for the chemicals perinaphthenone (white bars; a TRPA1 agonist), 1,2-
and 1,4-naphthoquinone (gray bars; also TRPA1 agonists), and a common
PAH pyrene (black bars).
Dose–response relationships for the activation
of humanTRPA1 and TRPV3 channels over-expressed in HEK-293 cells by chemicals
identified in WBSPM. Data are the mean and SEM for n ≥ 3 replicates. (A) 2,3-xylenol, (B) 2,4-xylenol, (C) 2,5-xylenol,
(D) 2,6-xylenol, (E) 3,4-xylenol, (F) 3,5-xylenol, (G) 2-ethylphenol,
(H) 3-ethylphenol, (I) 4-ethylphenol, (J) 2-methoxy-4-methylphenol,
(K) 5,8-dihydro-1-naphthol, and (L) 2,4-di-tert-butylphenol.(A) Relative peak areas for GC/MS peaks preliminarily
identified
as 2,3- and/or 3,4-xylenol (white bars), 5,8-dihydro-1-naphthol (gray
bars), and o-, m-, and/or p-cresol (black bars) for each of the samples tested as
TRPV3 agonists and assayed by PCA + PLS-DA. (B) Relative peak areas
for the chemicals perinaphthenone (white bars; a TRPA1 agonist), 1,2-
and 1,4-naphthoquinone (gray bars; also TRPA1 agonists), and a common
PAH pyrene (black bars).
Quantification of TRPV3 Agonists in Pine and Mesquite PM
The concentrations of 2,3-, 2,4- and/or 2,5- and 3,4-xylenol in pine
and mesquite PM (0.43–2.1 μm) were 0.3, 0.3, and 0.03%
by weight (μg/mg total PM). The concentration of 5,8-dihydro-1-naphthol
was 0.03%. A GC-MS extracted ion chromatogram from quantitative analysis
of pine PM (0.65–1.1 μm) is shown in Figure , highlighting the presence
of multiple cresol (numbers 1, 3, and 4) and xylenol (numbers 2, 6,
7, 10, and 11) analogues, and analytes not previously identified using
the metabolomics approach; 2- and/or 3-, and 4-ethyl phenol (numbers
5 and 9), and 2-methoxy-4-methylphenol (number 8). Table summarizes the chromatographic
and spectral match criteria used to identify these components, while Figure shows the structures
and potency for the various substances tested as TRPV3 and TRPA1 agonists.
To summarize, cresol analogues did not activate TRPV3. Xylenol and
ethylphenol analogues activated TRPV3 with slightly different potency
and relative selectivity for TRPV3 versus TRPA1. Additionally, 2,4-di-tert-butylphenol, previously identified as a TRPA1 agonist
in the “black smoker” DEP, was a TRPV3 agonist.
Figure 6
Extracted ion
chromatogram highlighting the presence of cresol
(black trace; numbers 1, 3, and 4), xylenols and ethyl phenols (blue
trace; numbers 2, 5, 6, 7, 9, 10, and 11), and 2-methoxy-4-methylphenol
(red trace; number 8). The reader is referred to Table for additional details regarding
the identification of and GC-MS characteristics of these compounds.
Table 1
Summary of GC/MS
Analysis of Pine
Particulate Matter, Highlighting the Cresol and Xylenol Analogues
as Well as 2-Methoxy-4-methylphenol in the Chromatograma
chemical name
number
on chromatogram in Figure 6
retention time (min); m/z
match quality scoreb
2-methyphenol (o-cresol)
1
6.7; 108
86
2,6-dimethylphenol (xylenol)
2
6.7; 122
47
3- and/or 4-methyphenol (m-, p-cresol)
3, 4
6.9; 122
90/86
2- and/or 3-ethylphenol
5
7.3; 122
72/72
2,4- and/or 2,5-dimethylphenol (xylenol)
6, 7
7.4; 108
91/87
2-methoxy-4-methylphenol
8
7.6; 138
90
4-ethylphenol
9
7.7; 122
86
2,3- and/or 3,5-dimethylphenol (xylenol)
10
7.8; 122
91/91
3,4-dimethylphenol (xylenol)
11
8.2; 122
72
Retention times, m/z values, and spectra were verified relative to
authentic standards.
From NIST08 Library.
Extracted ion
chromatogram highlighting the presence of cresol
(black trace; numbers 1, 3, and 4), xylenols and ethyl phenols (blue
trace; numbers 2, 5, 6, 7, 9, 10, and 11), and 2-methoxy-4-methylphenol
(red trace; number 8). The reader is referred to Table for additional details regarding
the identification of and GC-MS characteristics of these compounds.Retention times, m/z values, and spectra were verified relative to
authentic standards.From NIST08 Library.
TRPV3 Expression
and Function in Lung Cells
TRPV3 expression
in primary bronchial epithelial cells[41] and lung cancer cells[42] has been reported.
Here, the expression of TRPV3 mRNA in A549, BEAS-2B, Lobar bronchial,
and NHBE cells was quantified by qPCR (Figure A) and Western blot (Figure B). TRPV3 protein expression was observed
in A549, BEAS-2B, Lobar, and NHBE cells, which was confirmed by functional
studies (Figure C).
TRPV3 activity was observed in A549 and Lobar bronchial cells, and
to a lesser extent in NHBE and BEAS-2B cells using drofenine, carvacrol,
and pine PM as TRPV3 agonists (Figure C). Note, drofenine activates TRPV3, but not TRPA1,[31] while both carvacrol and pine PM activate TRPV3
and TRPA1. Additionally, NHBE cells do not perform as well in calcium
assays and therefore minimal calcium flux was observed. These data
show that both TRPV3 and A1 likely contribute to the responses of
these cells to pine PM, with the relative contribution being determined
by the relative levels of expression of these channels in the specific
cell type.
Figure 7
(A) mRNA expression data for TRPA1 and TRPV3 in human lung epithelial
cell lines. (B) Protein expression data for TRPV3 in human lung epithelial
cells. BEAS-2B TRPV3-OE cells are used as a positive control producing
a band at ∼90 kDa. Each bar for both protein and mRNA represents
three biological replicates over three passages. NHBEs are from three
different donors. (C) Ca2+ flux in response to various
TRPA1 and TRPV3 agonists in human lung epithelial cells. Drofenine
is selective for TRPV3, while pine PM and carvacrol activate both
TRPA1 and TRPV1. Data are the mean and SEM for n =
3 replicates.
(A) mRNA expression data for TRPA1 and TRPV3 in human lung epithelial
cell lines. (B) Protein expression data for TRPV3 in human lung epithelial
cells. BEAS-2BTRPV3-OE cells are used as a positive control producing
a band at ∼90 kDa. Each bar for both protein and mRNA represents
three biological replicates over three passages. NHBEs are from three
different donors. (C) Ca2+ flux in response to various
TRPA1 and TRPV3 agonists in human lung epithelial cells. Drofenine
is selective for TRPV3, while pine PM and carvacrol activate both
TRPA1 and TRPV1. Data are the mean and SEM for n =
3 replicates.
Cytotoxicity of WBSPM and
Pure TRPV3 Agonists in Lung Cells
The LD50 for
pine PM was 18 μg/cm2 in
BEAS-2B cells and 3 μg/cm2 in TRPV3-OE BEAS-2B cells
(Figure A). In A549
cells, the EC50 for pine and mesquite PM were 35 and >100
μg/cm2, 11 and 10 μg/cm2 in NHBE
cells, and 13 μg/cm2 for pine PM in Lobar cells (data
not shown). TRPV3 over-expression also increased the cytotoxicity
of 3,5-xylenol and 2,4-di-tert-butylphenol, but not
2,4-xylenol (Figures B–D).
Figure 8
Cytotoxicity data for (A) pine PM (0.43–0.65 μm),
(B) 2,4-xylenol, (C) 3,4-xylenol, and (D) 2,4-di-tert-butylphenol in BEAS-2B and TRPV3-OE BEAS-2B cells. Data represent
the mean and SEM from n ≥ 4 replicates from
two independent experiments. Statistical analysis was determined by
2-way ANOVA using and the Bonferonni post-test. *indicates p < 0.05, **p < 0.01, ***p < 0.001, and **** p < 0.001.
Cytotoxicity data for (A) pine PM (0.43–0.65 μm),
(B) 2,4-xylenol, (C) 3,4-xylenol, and (D) 2,4-di-tert-butylphenol in BEAS-2B and TRPV3-OE BEAS-2B cells. Data represent
the mean and SEM from n ≥ 4 replicates from
two independent experiments. Statistical analysis was determined by
2-way ANOVA using and the Bonferonni post-test. *indicates p < 0.05, **p < 0.01, ***p < 0.001, and **** p < 0.001.
Relative Role of TRPV3
in WBSPM Cytotoxicity
Because
pine PM and the pure TRPV3 agonists in WBPSM also activate TRPA1,
the relative roles for TRPV3 and TRPA1 were further explored. Transcriptomic
analysis of BEAS-2B and TRPV3-OE BEAS-2B cells revealed an up-regulation
of TRPA1 and TRPV4 in the TRPV3-OE cells; TRPV1 expression was unchanged
(Figure ). BEAS-2B
and TRPV3-OE BEAS-2B cells were subsequently treated with LD50 concentrations of pine PM in the presence of increasing concentrations
of the following TRP channel antagonists: HC-030031 (TRPA1), LJO-328
(TRPV1), 2-(5-trifluoromethyl-pyridin-2-ylsulfanyl)-1-(8-methyl-3,4-dihydro-2H-quinolin-1-yl)-ethanone (TRPV3), and HC-067047 (TRPV4)
(Figure A–D).
Inhibition of TRPA1, V1, and V4 failed to reduce the cytotoxicity
of pine PM, but inhibition of TRPV3 afforded partial protection in
both BEAS-2B and TRPV3-OE cells (note: the TRPV3 antagonist was also
cytotoxic at concentrations above 20–30 μM).
Figure 9
(A) Log ratio/mean
average plot of mRNA sequencing data comparing
the basal expression of TRP genes as a function of TRPV3 over-expression.
TRP channel genes are highlighted in blue with features appearing
at values >0 being over-expressed in TRPV3-OE BEAS-2B cells relative
to BEAS-2B cells. (B) Graphical representation of fold changes in
TRP gene mRNA expression. All data points represent averages from
duplicate sequencing runs.
Figure 10
Inhibition of the cytotoxicity of pine PM (10 μg/cm2) in BEAS-2B and in BEAS-2B TRPV3-OE cells using (A) the TRPA1 antagonist
HC-030031, (B) the TRPV1 antagonist LJO-328, (C) The
TRPV3 antagonist 2-(5-trifluoromethyl-pyridin-2-ylsulfanyl)-1-(8-methyl-3,4-dihydro-2H-quinolin-1-yl)-ethanone, and (D) the TRPV4 antagonist
HC-067047. Data represent the mean and SEM from n ≥ 4 replicates from two independent experiments. Statistical
analysis was determined by two-way ANOVA using and the Bonferonni
post-test. *, p < 0.05; **, p < 0.01; ***, p < 0.001; and ****, p < 0.001.
(A) Log ratio/mean
average plot of mRNA sequencing data comparing
the basal expression of TRP genes as a function of TRPV3 over-expression.
TRP channel genes are highlighted in blue with features appearing
at values >0 being over-expressed in TRPV3-OE BEAS-2B cells relative
to BEAS-2B cells. (B) Graphical representation of fold changes in
TRP gene mRNA expression. All data points represent averages from
duplicate sequencing runs.Inhibition of the cytotoxicity of pine PM (10 μg/cm2) in BEAS-2B and in BEAS-2BTRPV3-OE cells using (A) the TRPA1 antagonist
HC-030031, (B) the TRPV1 antagonist LJO-328, (C) The
TRPV3 antagonist 2-(5-trifluoromethyl-pyridin-2-ylsulfanyl)-1-(8-methyl-3,4-dihydro-2H-quinolin-1-yl)-ethanone, and (D) the TRPV4 antagonist
HC-067047. Data represent the mean and SEM from n ≥ 4 replicates from two independent experiments. Statistical
analysis was determined by two-way ANOVA using and the Bonferonni
post-test. *, p < 0.05; **, p < 0.01; ***, p < 0.001; and ****, p < 0.001.
Role of TRPV3 in Bronchial Hypersensitivity
Treatment
of mice with 0.5 mg/kg pine PM (0.43–1.1 μm) via oropharyngeal
aspiration every other day for 6 days, increased airway sensitivity
to acute methacholine challenge. Dosing scheme is shown in Figure A. Changes in airway resistance as a function of methacholine
dose and treatment with either pine PM, alone or in combination with
a TRPV3 antagonist, is summarized in Figure B,C. Pre- and co-treatment of mice with
the TRPV3 antagonist attenuated the increase in sensitivity to methacholine
and changes in airway resistance suggesting a role for TRPV3 in the
development of sub-acute airway hypersensitivity to methacholine.(A)
Methacholine dose–response curves for changes in airway
resistance in saline (black; n = 5), pine PM-treated
(gray; n = 5), TRPV3-antagonist treated (dashed black; n = 5), and pine + TRPV3-antagonist cotreated (dashed gray; n = 5) C57BL/6 mice. Data are the mean ± standard error
of the mean (n = 5). Data were analyzed by two-way
ANOVA and a Bonferroni post-test comparing all groups: Differences
compared to saline treatment are indicated as p <
0.05 (*), p < 0.01(**). (B) Comparison of changes
in airway resistance at the 25 mg/mL methacholine dose. Data are the
mean ± standard error of the mean (n = 5) and
were analyzed by one-way ANOVA with a Newman–Keuls post-test; p < 0.05 (*), p < 0.01(**).
Discussion
This
study characterized TRPV3 in lung cells, its activation by
selected wood smoke particles and specific chemical constituents thereof,
and responses of lung cells and lungs of mice as a function of TRPV3
activity. The results provide new insight into the roles of TRPV3
in lung epithelial cells and evidence supporting a relationship between
TRPV3 and some of the known, but mechanistically undefined, pneumotoxic
properties that have been reported previously for WBSPM.Environmental
PM is physically and chemically diverse. The precise
composition of combustion-generated PM varies by origin, combustion
conditions, age, and other factors. Consequently, the biological sensors
that detect PM in the airways, and the effects that PM has on lung
cells/tissue, can vary. Figure shows that TRPA1 and TRPV3 were activated by pine and mesquite
PM. Activation of TRPV3 by WBSPM was not universal for all forms of
WBSPM but it was unique from TRPA1, ultimately shown to be driven
by specific chemicals occurring in only certain types of PM; notably,
pine and mesquite PM < 2.1 μm containing xylenols, ethyl
phenols, 2-methoxy-4-methylphenol, and 5,8-dihydronapthol (Figures –6; Table ). While it is likely that other TRPV3 agonists exist in the
pine and mesquite PM, as well as in other forms of environmental WBSPM
that humans may be exposed to, these results link the presence of
specific chemicals to the activation of a novel biological target.
These results also further underscore the concept that the biological
effects of a given form of PM are highly dependent upon the chemical
composition of the PM, and the ability of specific chemicals to interact
with and activate explicit biological sensors and pathways.A characteristic adverse effect of WBSPM inhalation is lung epithelial
cell cytotoxicity.[43,44] Indeed, both pine and mesquite
PM were cytotoxic to a variety of lung cells in which TRPV3 was expressed
(Figures and 8). Both WBSPM and pure TRPV3 agonists were cytotoxic
to lung epithelial cells and their toxicity involved TRPV3, with pine
PM being attenuated by a TRPV3 antagonist (Figure and 10). Interestingly,
it was also found that TRPV3-OE BEAS-2B expressed higher levels of
TRPA1 and TRPV4 (Figure ). This was an intriguing finding since TRPA1 expression in BEAS-2B
cells, and other similar lung cells, is typically low/non-detectable,
with the exception that we have recently discovered that heterozygosity
for the TRPV1I585V polymorphism (rs8065080) is associated with increased
TRPA1 expression in NHBE cells, and perhaps increased sensitivity
to environmental pollutants.[35] Of note,
the NHBE cells used in this study expressed wild-type TRPV1, and therefore
expression of TRPA1 mRNA was not detected (Figure A). Regardless, the results in Figures –10 prompted us to investigate whether TRPA1 may also
contribute to the acute cytotoxicity of pine PM and pure TRPV3 agonists,
potentially explaining the heightened sensitivity of the TRPV3-OE
cells to these materials. However, inhibition of TRPA1, as well as
TRPV1, and TRPV4, did not protect cells from cytotoxicity indicating
a prominent role for TRPV3 in mediating this outcome.Like many
types of inhaled PM, WBSPM affects the lungs. Relevant
to this work, short-term exposure to WBSPM (PM10 ≥ 0.15–0.2
μg/m3) has been shown to correlate with increased
rates of hospital visits for respiratory complications, including
the exacerbation of asthma and COPD.[9−18] We have previously identified TRPA1 as a target for WBSPM, specifically
electrophiles present in these materials.[30] Activation of TRPA1 in the lungs has been shown to stimulate the
cough reflex and bronchoconstriction, decrease respiratory drive,
and promote neurogenic inflammation.[45] Gain
of function polymorphisms in TRPA1 are also associated with poorer
asthma control.[34] Thus, interactions between
TRPA1 and WBSPM likely contribute to the acute irritant and pro-inflammatory
effects of inhaled WBSPM. However, a role for TRPV3 has not yet been
described.Like TRPA1, TRPV3 expression has been reported to
occur in TRPV1-positive
dorsal root and trigeminal ganglia, and vagal afferent neurons, which
are relevant to respiratory physiology.[46,47] Additionally,
a certain amount of synergy appears to exist between TRPV3 and other
TRP channels in these tissues. For example, Wu et al. suggest that
while TRPV3 expression is lower than that of TRPV1, activation of
TRPV3 may potentiate TRPV1 activation in vagal afferent neurons.[46] Intuitively, stimulation of TRPV3 in TRPV1-positive
neurons and/or sensitization of TRPV1 should correlate with a stimulation
of irritant responses similar to those described above for TRPA1.
As such, this may be a mechanism by which WBSPM adversely affects
the respiratory system. However, others have also reported that TRPV3
agonists, including thymol, have anti-tussive properties,[48] similar to menthol, which activates TRPM8 to
attenuate responses to TRPA1 agonists.[48,49] Our data also
suggest the possibility of interplay between TRPV3 expression/function
and TRPA1 expression/function in epithelial cells, which could also
affect the respiratory tract through a variety of mechanisms. Regardless,
further investigation into the roles of TRPV3 in WBSPM pneumotoxicity
is needed in order to fully understand the mechanistic basis for the
results shown in Figure , that sub-acute pulmonary exposure of mice to pine PM sensitized
mice to methacholine in an apparent TRPV3-dependent manner. While
it remains unclear exactly how this sensitization occurs—whether
it involved direct activation of TRPV3 in neurons or epithelial cells,
changes in TRPA1, V3, or even V4 expression, cytotoxicity and loss
of epithelial cells, inflammation, or other mechanisms—these
data indicate a role for TRPV3 in the development of deleterious respiratory
effects elicited by pine and perhaps other WBSPM.In summary,
TRPV3 has been identified as a new molecular sensor
for WBSPM in lung epithelial cells. The activation of TRPV3 is dependent
upon the specific chemical composition of the WBSPM, suggesting that
TRPV3 may play variable roles in WBSPM-induced pneumotoxicity,
albeit varying as a function of the material being burned, the conditions
used to burn the material, and other factors. Additionally, TRPV3
appears to play a role in determining lung cell and airway sensitivity
to WBSPM. Accordingly, TRPV3 should be considered in future studies
aimed at understanding mechanisms of lung injury and lung disorders
and diseases associated with WBSPM exposures.
Authors: L Barregard; G Sällsten; L Andersson; A-C Almstrand; P Gustafson; M Andersson; A-C Olin Journal: Occup Environ Med Date: 2007-08-17 Impact factor: 4.402
Authors: Cassandra E Deering-Rice; Chris Stockmann; Erin G Romero; Zhenyu Lu; Darien Shapiro; Bryan L Stone; Bernhard Fassl; Flory Nkoy; Derek A Uchida; Robert M Ward; John M Veranth; Christopher A Reilly Journal: J Biol Chem Date: 2016-10-07 Impact factor: 5.157
Authors: Haoxing Xu; I Scott Ramsey; Suhas A Kotecha; Magdalene M Moran; Jayhong A Chong; Deborah Lawson; Pei Ge; Jeremiah Lilly; Inmaculada Silos-Santiago; Yu Xie; Peter S DiStefano; Rory Curtis; David E Clapham Journal: Nature Date: 2002-06-23 Impact factor: 49.962
Authors: Pernille Høgh Danielsen; Elvira Vaclavik Bräuner; Lars Barregard; Gerd Sällsten; Maria Wallin; Ryszard Olinski; Rafal Rozalski; Peter Møller; Steffen Loft Journal: Mutat Res Date: 2008-04-14 Impact factor: 2.433
Authors: A K Vogt-Eisele; K Weber; M A Sherkheli; G Vielhaber; J Panten; G Gisselmann; H Hatt Journal: Br J Pharmacol Date: 2007-04-10 Impact factor: 8.739
Authors: Nam D Nguyen; Tosifa A Memon; Katherine L Burrell; Marysol Almestica-Roberts; Emmanuel Rapp; Lili Sun; Abigail F Scott; Joseph E Rower; Cassandra E Deering-Rice; Christopher A Reilly Journal: Mol Pharmacol Date: 2020-09-16 Impact factor: 4.436
Authors: Tosifa A Memon; Nam D Nguyen; Katherine L Burrell; Abigail F Scott; Marysol Almestica-Roberts; Emmanuel Rapp; Cassandra E Deering-Rice; Christopher A Reilly Journal: Toxicol Sci Date: 2020-04-01 Impact factor: 4.849
Authors: Cassandra E Deering-Rice; Tosifa Memon; Zhenyu Lu; Erin G Romero; James Cox; Thomas Taylor-Clark; John M Veranth; Christopher A Reilly Journal: Chem Res Toxicol Date: 2019-04-15 Impact factor: 3.739
Authors: Noemi D Paguigan; Jortan O Tun; Lee S Leavitt; Zhenjian Lin; Kevin Chase; Cheryl Dowell; Cassandra E Deering-Rice; Albebson L Lim; Manju Karthikeyan; Ronald W Hughen; Jie Zhang; Randall T Peterson; Christopher A Reilly; Alan R Light; Shrinivasan Raghuraman; J Michael McIntosh; Baldomero M Olivera; Eric W Schmidt Journal: ACS Chem Neurosci Date: 2021-07-02 Impact factor: 5.780